Scholarlink

<p>Receptor tyrosine kinases are key regulators of various fundamental cellular processes, and dysregulation of their activities may lead to many human diseases including cancer. EphA2 is a member of the Eph subfamily of receptor tyrosine kinases that play an important role in regulating tissue patterning, homeostasis, and regeneration. Accumulating evidence indicates that EphA2 is a critical regulator of cancer development and progression and can function as both a tumor suppressor and an oncogenic driver. When acting as an oncogenic driver, EphA2 can promote tumor initiation, growth, invasion, metastasis, stemness, and angiogenesis by activating or enhancing the oncogenic signaling pathways. High expression of EphA2 in a wide range of human tumor tissues is closely associated with poor prognosis, thus it is a very promising target for cancer treatment. A number of studies on EphA2-targeted cancer treatment are currently at the clinical trial stage. In this review, we discuss the oncogenic roles and mechanisms of action of EphA2 in cancer development and progression, which could provide novel insights into EphA2-targeted cancer treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

EphA2 as an oncogenic driver: roles and mechanisms of action in cancer

  • 期刊论文

  • 发表日期：

    2026年6月30日

查看全文
  • Hanbing Song,
  • Ning Qin,
  • Xiaohe Feng,
  • Chen Han,
  • Yun Liu,
  • Yunsha Jia,
  • Peiyuan Lu

摘要

Receptor tyrosine kinases are key regulators of various fundamental cellular processes, and dysregulation of their activities may lead to many human diseases including cancer. EphA2 is a member of the Eph subfamily of receptor tyrosine kinases that play an important role in regulating tissue patterning, homeostasis, and regeneration. Accumulating evidence indicates that EphA2 is a critical regulator of cancer development and progression and can function as both a tumor suppressor and an oncogenic driver. When acting as an oncogenic driver, EphA2 can promote tumor initiation, growth, invasion, metastasis, stemness, and angiogenesis by activating or enhancing the oncogenic signaling pathways. High expression of EphA2 in a wide range of human tumor tissues is closely associated with poor prognosis, thus it is a very promising target for cancer treatment. A number of studies on EphA2-targeted cancer treatment are currently at the clinical trial stage. In this review, we discuss the oncogenic roles and mechanisms of action of EphA2 in cancer development and progression, which could provide novel insights into EphA2-targeted cancer treatment.